Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chlorin e6 derivative STBF is a second-generation photosensitizer used in photodynamic therapy (PDT). It is a derivative of chlorin e6 (Ce6), a porphyrin-like molecule derived from chlorophyll. STBF is specifically being evaluated for dermatological applications, most notably for the treatment of rosacea. In the STBF-PDT procedure, the drug is applied topically to the affected skin and subsequently activated by a specific wavelength of light (typically red light around 630 nm). This activation leads to the generation of reactive oxygen species (ROS), such as singlet oxygen, which induce anti-inflammatory and antimicrobial effects, target sebaceous gland activity, and may reduce *Demodex* mite populations. Clinical studies, including those conducted by the Shanghai Skin Disease Hospital, have compared the efficacy and safety of STBF-PDT against standard systemic treatments like doxycycline for rosacea management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlorin e6 derivative STBF.